Article info
Clinical ethics
Reconsidering scarce drug rationing: implications for clinical research
- Correspondence to Dr Zev M Nakamura, Psychiatry, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA; zev_nakamura{at}med.unc.edu
Citation
Reconsidering scarce drug rationing: implications for clinical research
Publication history
- Received July 24, 2020
- Revised October 15, 2020
- Accepted October 27, 2020
- First published November 27, 2020.
Online issue publication
January 07, 2022
Article Versions
- Previous version (7 January 2022).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ.
Other content recommended for you
- Blood product use for radiological/nuclear trauma: product development and US regulatory considerations
- Paediatric off-label use of drugs in Gansu, China: a multicentre cross-sectional study
- Improving access to medicines: lessons from 10 years of drug reforms in China, 2009–2020
- Unlicensed and off label drug use in paediatric wards: prospective study
- Analysis of the impact of antimicrobial management and rational use of antibiotics
- US drug shortages are set to reach record high in 2011, report says
- A prospective study of off-label use of, abuse of, and dependence on nicotine inhaler
- Wernicke encephalopathy after Roux-en-Y gastric bypass in a young patient
- Affordability and availability of off-patent drugs in the United States—the case for importing from abroad: observational study
- Off label prescribing in children